Irinotecan therapy in adults with recurrent or progressive malignant glioma. 1999

H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. fried003@mc.duke.edu

OBJECTIVE To determine the activity, toxicity, and pharmacokinetics of irinotecan (CPT-11, Camptosar; Pharmacia & Upjohn, Kalamazoo, MI) in the treatment of adults with progressive, persistent, or recurrent malignant glioma. METHODS Patients with progressive or recurrent malignant gliomas were enrolled onto this study between October 1996 and August 1997. CPT-11 was given as a 90-minute intravenous (i.v.) infusion at a dose of 125 mg/m2 once weekly for 4 weeks followed by a 2-week rest, which comprised one course. Plasma concentrations of CPT-11 and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), were determined in a subset of patients. RESULTS All 60 patients who enrolled (36 males and 24 females) were treated with CPT-11 and all were assessable for toxicity, response, and survival. Pharmacokinetic data were available in 32 patients. Nine patients (15%; 95% confidence interval, 6% to 24%) had a confirmed partial response, and 33 patients (55%) achieved stable disease lasting more than two courses (12 weeks). Toxicity observed during the study was limited to infrequent neutropenia, nausea, vomiting, and diarrhea. CPT-11, SN-38, and SN-38G area under the plasma concentration-time curves through infinite time values in these patients were approximately 40%, 25%, and 25%, respectively, of those determined previously in patients with metastatic colorectal cancer not receiving antiepileptics or chronic dexamethasone treatment. CONCLUSIONS Response results document that CPT-11, given with a standard starting dose and treatment schedule, has activity in patients with recurrent malignant glioma. However, the low incidence of severe toxicity and low plasma concentrations of CPT-11 and SN-38 achieved in this patient population suggest that concurrent treatment with anticonvulsants and dexamethasone enhances drug clearance.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009837 Oligodendroglioma A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655) Oligodendroblastoma,Anaplastic Oligodendroglioma,Mixed Oligodendroglioma-Astrocytoma,Mixed Oligodendroglioma-Ependymoma,Oligodendroglioma, Adult,Oligodendroglioma, Childhood,Oligodendroglioma, Well-Differentiated,Well-Differentiated Oligodendroglioma,Adult Oligodendroglioma,Adult Oligodendrogliomas,Anaplastic Oligodendrogliomas,Childhood Oligodendroglioma,Childhood Oligodendrogliomas,Mixed Oligodendroglioma Astrocytoma,Mixed Oligodendroglioma Ependymoma,Mixed Oligodendroglioma-Astrocytomas,Mixed Oligodendroglioma-Ependymomas,Oligodendroblastomas,Oligodendroglioma, Anaplastic,Oligodendroglioma, Well Differentiated,Oligodendroglioma-Astrocytoma, Mixed,Oligodendroglioma-Astrocytomas, Mixed,Oligodendroglioma-Ependymoma, Mixed,Oligodendroglioma-Ependymomas, Mixed,Oligodendrogliomas,Oligodendrogliomas, Adult,Oligodendrogliomas, Anaplastic,Oligodendrogliomas, Childhood,Oligodendrogliomas, Well-Differentiated,Well Differentiated Oligodendroglioma,Well-Differentiated Oligodendrogliomas
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D005260 Female Females
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
April 2004, Neuro-oncology,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
October 2005, Cancer,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
January 2005, Cancer,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
October 2004, Expert review of anticancer therapy,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
August 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
December 2002, Current treatment options in oncology,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
February 2004, American journal of clinical oncology,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
December 2011, Neuro-oncology,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
July 2009, Cancer,
H S Friedman, and W P Petros, and A H Friedman, and L J Schaaf, and T Kerby, and J Lawyer, and M Parry, and P J Houghton, and S Lovell, and K Rasheed, and T Cloughsey, and E S Stewart, and O M Colvin, and J M Provenzale, and R E McLendon, and D D Bigner, and I Cokgor, and M Haglund, and J Rich, and D Ashley, and J Malczyn, and G L Elfring, and L L Miller
July 2005, Expert review of neurotherapeutics,
Copied contents to your clipboard!